Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

NASDAQ:ONCT

Overview | Financials
Company Name Oncternal Therapeutics, Inc.
Symbol ONCT
Currency USD
Price 8.66
Market Cap 25,630,569
Dividend Yield 0%
52-week-range 5.57 - 13.2
Industry Biotechnology
Sector Healthcare
CEO Dr. James B. Breitmeyer M.D., Ph.D.
Website https://www.oncternal.com

An error occurred while fetching data.

About Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of

Related Stocks

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

45 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.665 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

5.9 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

3.18 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.39 USD

Financials

Numbers are in millions USD

Numbers are in millions USD